Literature DB >> 34378828

Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer.

Shane S Neibart1, Daniella E Portal1, Jyoti Malhotra2, Salma K Jabbour3, Jason A Roy4, Brian L Strom5.   

Abstract

PURPOSE: Non-infectious pneumonitis (NIP) is a common complication of treatments for lung cancer. We know of no existing validated algorithm for identifying NIP in claims databases, limiting our ability to understand the morbidity and mortality of this toxicity in real-world data.
METHODS: Electronic health records (EHR), cancer registry, and administrative data from a National Cancer Institute-designated comprehensive cancer center were queried for patients diagnosed with lung cancer between 10/01/2015-12/31/2020. Health insurance claims were searched for ICD-10-CM codes that indicate an inpatient or outpatient diagnosis with possible NIP. A 20-code (Algorithm A) and 11-code (Algorithm B) algorithm were tested with and without requiring prescription with corticosteroids. Cases with a diagnosis of possible NIP in the 6 months before their first lung cancer diagnosis were excluded. The algorithms were validated by reviewing the EHR. The positive predictive value (PPV) for each algorithm was computed with 95% confidence intervals (CI).
RESULTS: Seventy patients with lung cancer had a diagnosis code compatible with NIP: 36 (51.4%) inpatients and 34 (48.6%) outpatients. The PPV of Algorithm A was 77.1% (95% CI: 65.6-86.3). The PPV of Algorithm B was 86.9% (95% CI: 75.8-94.2). Requiring a documented prescription for a systemic corticosteroid improved the PPV of both Algorithm A and Algorithm B: 92.5% (95% CI: 79.6-98.4) and 100.0% (95% CI: 90.0-100.0), respectively.
CONCLUSIONS: This study validated ICD-10-CM and prescription-claims-based definitions of NIP in lung cancer patients. All algorithms have at least reasonable performance. Enriching the algorithm with corticosteroid prescription records results in excellent performance.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  administrative claims data; algorithm; lung cancer; pneumonitis; validation

Mesh:

Year:  2021        PMID: 34378828      PMCID: PMC8578340          DOI: 10.1002/pds.5339

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  18 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

Authors:  Salma K Jabbour; Abigail T Berman; Roy H Decker; Yong Lin; Steven J Feigenberg; Scott N Gettinger; Charu Aggarwal; Corey J Langer; Charles B Simone; Jeffrey D Bradley; Joseph Aisner; Jyoti Malhotra
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

3.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

4.  Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer.

Authors:  Kellie J Ryan; Damion Nero; Bruce A Feinberg; Choo Hyung Lee; Rodrigo Pimentel; Ajeet Gajra; Jonathan K Kish; Brian Seal
Journal:  Future Oncol       Date:  2019-12-05       Impact factor: 3.404

5.  Daily Image Guidance With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer.

Authors:  Nikhil Yegya-Raman; Sinae Kim; Matthew P Deek; Diana Li; Apar Gupta; Laura Bond; Abhishek Dwivedi; Joel K Braver; Meral Reyhan; Akaash Mittal; Bin Gui; Jyoti Malhotra; Joseph Aisner; Salma K Jabbour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-30       Impact factor: 7.038

6.  A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Authors:  Jyoti Malhotra; Petros Nikolinakos; Ticiana Leal; Jonathan Lehman; Daniel Morgensztern; Jyoti D Patel; John M Wrangle; Giuseppe Curigliano; Laurent Greillier; Melissa L Johnson; Neal Ready; Gilles Robinet; Satwant Lally; David Maag; Ricardo Valenzuela; Vincent Blot; Benjamin Besse
Journal:  J Thorac Oncol       Date:  2021-02-27       Impact factor: 15.609

7.  A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Authors:  Greg A Durm; Salma K Jabbour; Sandra K Althouse; Ziyue Liu; Ahad A Sadiq; Robin T Zon; Shadia I Jalal; Goetz H Kloecker; Michael J Williamson; Karen L Reckamp; Robert M Langdon; Ebenezer A Kio; Ryan D Gentzler; Bamidele A Adesunloye; Wael A Harb; Radhika V Walling; Michael L Titzer; Nasser H Hanna
Journal:  Cancer       Date:  2020-07-22       Impact factor: 6.860

8.  Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Daichi Fujimoto; Ryoji Kato; Takeshi Morimoto; Ryoko Shimizu; Yuki Sato; Mariko Kogo; Jiro Ito; Shunsuke Teraoka; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Keisuke Tomii
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

9.  Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.

Authors:  Fangjuan Li; Hui Liu; Hongyu Wu; Shixiong Liang; Yaping Xu
Journal:  Radiat Oncol       Date:  2021-04-13       Impact factor: 3.481

10.  Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data.

Authors:  Jerzy E Tyczynski; Ravi Potluri; Ryan Kilpatrick; Debasish Mazumder; Anirban Ghosh; Alexander Liede
Journal:  Oncol Ther       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.